XML 26 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Note 4 - Balance Sheet Components
12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

4. Balance Sheet Components

 

Property and Equipment, net

 

Property and equipment, net consisted of the following (in thousands):

 

  

December 31,

 
  

2023

  

2022

 

Leasehold improvements

 $2,519  $2,519 

Laboratory equipment

  1,247   1,118 

Furniture, fixtures and equipment

  966   966 

Software

  272   289 

Construction in progress

     22 
   5,004   4,914 

Less: Accumulated depreciation and amortization

  (3,476)  (2,953)
  $1,528  $1,961 

 

Depreciation expense for the years ended  December 31, 2023 and 2022, was $0.5 million and $0.7 million, respectively.

 

Intangible Assets, net

 

Intangible assets primarily consist of a license to utilize certain patents, know-how and technology relating to the Company’s NPS for biomedical applications acquired from Old Dominion University Research Foundation (ODURF), Eastern Virginia Medical School (EVMS), and the University of Southern California. In addition, the Company entered into a sponsored research agreement (“SRA”) with Old Dominion University’s Frank Reidy Research Center for Bioelectrics, a leading research organization in the field, which includes certain intellectual property rights arising from the research. The Company is amortizing the intangible assets over an estimated useful life of 12 years.

 

Intangible assets, net consisted of the following (in thousands):

 

  

December 31,

 
  

2023

  

2022

 

Acquired patents and licenses

 $7,985  $7,985 

Less: Accumulated amortization

  (6,099)  (5,434)
  $1,886  $2,551 

 

A schedule of the amortization of intangible assets is as follows (in thousands):

 

Years ending December 31:

    

2024

 $665 

2025

  665 

2026

  556 
  $1,886 

 

Accrued Expenses

 

Accrued expenses consisted of the following (in thousands):

 

  

December 31,

 
  

2023

  

2022

 

Compensation expense

 $3,199  $1,377 

Director and officer liability insurance (Note 12)

     571 

Clinical trial fees and costs

  84   64 

Professional fees

  343   318 

Warranty

     50 

Other

  188   215 
  $3,814  $2,595